Emmaus Life Sciences, Inc.
EMMA
$0.0165
$0.001510.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.65M | 20.43M | 19.97M | 25.35M | 29.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.65M | 20.43M | 19.97M | 25.35M | 29.60M |
| Cost of Revenue | 1.20M | 1.08M | 903.00K | 1.17M | 1.34M |
| Gross Profit | 15.45M | 19.35M | 19.07M | 24.18M | 28.26M |
| SG&A Expenses | 16.69M | 18.64M | 18.89M | 21.13M | 23.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.55M | 20.41M | 20.75M | 23.39M | 26.06M |
| Operating Income | -1.89M | 18.00K | -779.00K | 1.97M | 3.54M |
| Income Before Tax | -6.42M | -3.59M | -5.31M | -4.75M | -3.79M |
| Income Tax Expenses | 29.00K | -89.00K | -50.00K | -115.00K | -59.00K |
| Earnings from Continuing Operations | -6.45 | -3.50 | -5.26 | -4.63 | -3.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.45M | -3.50M | -5.26M | -4.63M | -3.73M |
| EBIT | -1.89M | 18.00K | -779.00K | 1.97M | 3.54M |
| EBITDA | -1.87M | 41.00K | -753.00K | 1.99M | 3.57M |
| EPS Basic | -0.10 | -0.05 | -0.08 | -0.08 | -0.07 |
| Normalized Basic EPS | -0.07 | -0.04 | -0.05 | -0.05 | -0.03 |
| EPS Diluted | -0.13 | -0.08 | -0.09 | -0.08 | -0.08 |
| Normalized Diluted EPS | -0.08 | -0.05 | -0.05 | -0.05 | -0.04 |
| Average Basic Shares Outstanding | 252.93M | 244.24M | 234.02M | 223.53M | 212.39M |
| Average Diluted Shares Outstanding | 351.79M | 343.10M | 318.75M | 308.26M | 297.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |